There were 1,067 press releases posted in the last 24 hours and 430,330 in the last 365 days.

Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday, October 3, 2018 at 3:30 pm PT in La Jolla, California.

The Cell & Gene Meeting on the Mesa is organized by the Alliance of Regenerative Medicine and the Stanford Stem Cell Clinical Center at UC San Diego. A live video webcast will be available at http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.

Media Contact:
Solid Biosciences
Kate Niazi-Sai
617-337-4680
media@solidbio.com

Investor Contact:
Kendall Investor Relations
Carlo Tanzi, Ph.D.
617-337-4680
investors@solidbio.com

SolidBioLogoDigitalRGB.png

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.